News
- Author:
- Ted Bosworth
Publish date: September 25, 2024
New extension data from phase 3 ofatumumab RRMS study, show lower long-term disability accumulation with early-start of the more potent therapy ove...
News
- Author:
- Ted Bosworth
Publish date: September 23, 2024
Despite theoretical benefits and an encouraging phase 2 study, a definitive phase 3 trial failed to associate sim...
News
- Author:
- Ted Bosworth
Publish date: September 23, 2024
In phase 3 RRMS trials, tolebrutinib showed no advantage over teriflunomide for a relapse endpoint, but a disability endpoint advantage might chang...
News
- Author:
- Ted Bosworth
Publish date: September 23, 2024
In patients with darker skin, the signs of seborrheic dermatitis can differ.
News
- Author:
- Ted Bosworth
Publish date: September 23, 2024
In patients with DIHS and many of the even more serious types of rashes traced to drug exposures, the delay to appearance of the rash from the time...
News
- Author:
- Ted Bosworth
Publish date: September 23, 2024
This initiative could be a critical step toward ensuring diversity in major clinical trials after years of stagnation, Dr. Valerie Harvey said.
News
- Author:
- Ted Bosworth
Publish date: September 19, 2024
The growing quantity of real-world data supporting hematopoietic stem cell transplant for MS is driving its growing routine application at centers ...
News
- Author:
- Ted Bosworth
Publish date: September 19, 2024
A meta-analysis strongly reinforcing the association between common comorbidities and increased MS activity is ch...
News
- Author:
- Ted Bosworth
Publish date: September 6, 2024
Postoperative atrial fibrillation risks is not altered with potassium supplementation for patients who recently had CV surgery, says study.
News
- Author:
- Ted Bosworth
Publish date: September 3, 2024
Class I recommendations have been issued for comorbidity, risk factor management goals, including those BP, HF, diabetes, etc.
News
- Author:
- Ted Bosworth
Publish date: July 25, 2024
Sutureless valves are an alternative to SAVR and TAVR, but are used less often and have less data.
News
- Author:
- Ted Bosworth
Publish date: July 9, 2024
New options in late stages of clinical testing for refractory gout promise to increase the chances of reaching the guideline uric acid target with ...
News
- Author:
- Ted Bosworth
Publish date: July 8, 2024
Numerous cases and case series presented at EULAR 2024 add to a rapidly growing collection of evidence that CAR T-cell therapy will be a meaningful...
News
- Author:
- Ted Bosworth
Publish date: July 5, 2024
The most recent of several studies exploring the impact of COVID-19 infection on children with asthma suggests vaccination reduces asthma symptoms ...
News
- Author:
- Ted Bosworth
Publish date: June 26, 2024
For JIA, a disease with limited options, a three-injection course of canakinumab was associated with durable control of disease in the absence of g...
